Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma
Breast Cancer Research and Treatment · 2025
DOI: 10.1007/s10549-024-07584-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von K Korpinen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland. kkhkor@utu.fi. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suomen Lääketieteen Säätiö, University of Turku.
Abstract (Originalsprache)
Purpose
Due to biological heterogeneity of breast carcinoma, predicting the individual response to neoadjuvant treatment (NAT) is complex. Consequently, there are no comprehensive, generally accepted practices to guide post-treatment follow-up. We present clinical and histopathological criteria to advance the prediction of disease outcome in NA-treated breast cancer.
Methods
A retrospective consecutive cohort of 257 NA-treated Finnish breast cancer patients with up to 13-year follow-up and the corresponding tissue samples of pre- and post-NAT breast and metastatic specimen were evaluated for prognostic impacts. All relevant clinical and biomarker characteristics potentially correlated with tumor response to NAT, course of disease, or outcome of breast cancer were included in the statistical analyses.
Results
The results highlight the intensified characterization of distinguished prognostic factors and previously overlooked histological features, e.g., mitotic and apoptotic activity. Particularly, decreased PR indicated 3.8-fold (CI 1.9–7.4, p = 0.0001) mortality risk, and a > 10.5-year shorter survival for the majority, > 75% of patients (Q1). Clinically applicable prognostic factors both preceding and following NAT were identified and compiled into heat maps to quantify mortality and recurrence risks. Combinations of risk factors for aggressive disease were exemplified as an interactive tool (bcnatreccalc.utu.fi) to illustrate the spectrum of disease outcomes.
Conclusion
The results emphasize the value of comprehensive evaluation of conventional patient and biomarker characteristics, especially concerning re-assessment of biomarkers, risk-adapted surveillance, and personalized treatment strategies. Future personalized NA-treatment strategies might benefit from models combining risk-adapted surveillance data and post-NAT re-assessed biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland. kkhkor@utu.fi.
- Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland.
- Department of Pathology, Turku University Hospital, Turku, Finland.
- Department of Biostatistics, University of Turku, Turku, Finland.
- Department of Oncology, Vaasa Central Hospital, Vaasa, Finland.
Förderung
- Suomen Lääketieteen Säätiö
- University of Turku
Zitieren
APA
Korpinen, K., Autere, T. A., Tuominen, J., Löyttyniemi, E., Eigeliene, N., Talvinen, K., & Kronqvist, P. (2025). Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07584-4
Vancouver
Korpinen K, Autere TA, Tuominen J, Löyttyniemi E, Eigeliene N, Talvinen K, et al. Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07584-4
BibTeX
@article{Korpinen2025,
author = {Korpinen, K and Autere, T A and Tuominen, J and Löyttyniemi, E and Eigeliene, N and Talvinen, K and Kronqvist, P},
title = {Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma},
journal = {Breast Cancer Research and Treatment},
year = {2025},
doi = {10.1007/s10549-024-07584-4}
}
EUVIMED